|
Speaker |
Presentation |
|
Ron Law, Lincolnshire, USA |
What could be interesting targets in atherosclerotic plaques |
|
Rudi Busse; Frankfurt |
Role of endothelium - why endothelial targets? |
|
Dennis Brümmer, Lexington, USA |
Osteopontin in atherosclerosis and injury |
|
Sylvia Heeneman; Maastricht, NL |
How to find a target |
|
Ulrich Dirnagl; Jan Klohs Berlin |
Imaging of inflammation in experimental stroke |
|
Rene Botnar; München |
MR imaging strategies for Gd-imaging |
|
Matthias Stuber; Baltimore; USA |
MR imaging strategies for Fe-imaging |
|
Samuel Wickline; St. Louis, USA |
Specific Gd-contrast agents |
|
Jörg Meding; Berlin |
Gadofluorin |
|
Matthias Taupitz; Berlin |
(Specific) iron oxide contrast agents |
|
Frank Seifert, Berlin |
Quantitative assessment of contrast agent charateristics (nuclear, optical, MR-iron, MR-Gd, etc.) |
|
G.J. Strijkers;Eindhoven, NL |
Lipid based multimodal contrast agents |
|
Ulrich Pison; Berlin |
PET, PET/CT |
|
Andreas Wunder; Berlin |
Optical imaging - results |
|
Dara Kraitchman, Baltimore, USA |
Stem cell imaging |
|
Henning Morawitz; Dresden |
Endothelial Targets |
|
Isabel Gonzalves, Malmö, S |
Oxidized LDL imaging |
|
Michael Gräfe; Berlin |
CD 40 imaging |
|
Kristof Graf; Berlin |
EDB-Fibronectin |
|
Philipp Stawowy; Berlin |
PCs - key regulators of cell matrix interaction in atheroscslerosis |
|
David Maintz; Münster |
Contrast enhanced MR imaging of coronary plaques in humans |
|
Paula Foster; London, Canada |
Imaging Cells Using MRI and Magnetic Nanoparticles |
|
Leo Hofstra; Maastricht, NL |
Annexin imaging |
|
David Sosnovik; Boston, USA |
Molecular Imaging (Boston) |
|
Zahi Fayad; New York, USA |
Molecular Imaging (New York) |
|
Mat Daemen; Maastricht, NL |
Which animal model is best suited to model human coronary artery plaque - and why |
|
Juergen Schneider, Oxford, UK |
(Ultra) High Field Animal Imaging |
|
Eike Nagel; Berlin |
From 3T to 7T and back |
|
Petra Schmalbrock, Cleveland; USA |
Human 7 Tesla imaging |
